Small molecules, big targets: drug discovery faces the protein–protein interaction challenge

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

Selective inhibition of BET bromodomains

Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · see citing works

New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays

Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,963 · see citing works

The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored

Szklarczyk, D., Franceschini, A., Kuhn, M., Simonovic, M., Roth, A. C., Mínguez, P., Doerks, T., Stark, M., Muller, J., Bork, P., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq973 · Cited by 3,469 · see citing works

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058 · see citing works

Principles of protein-protein interactions

Jones, S., & Thornton, J. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.13 · Cited by 2,684 · see citing works

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992 · see citing works

Anatomy of hot spots in protein interfaces

Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988 · see citing works

A Hot Spot of Binding Energy in a Hormone-Receptor Interface

Clackson, T., & Wells, J. A. (1995) · Science · doi:10.1126/science.7529940 · Cited by 1,987 · see citing works

The Future of Peptide‐based Drugs

Craik, D. J., Fairlie, D. P., Liras, S. I., & Price, D. A. (2012) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12055 · Cited by 1,984 · see citing works

Reaching for high-hanging fruit in drug discovery at protein–protein interfaces

Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 1,963 · see citing works

Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family

Filippakopoulos, P., Picaud, S., Mangos, M., Keates, T., Lambert, J., Baršytė-Lovejoy, D., Felletár, I., Volkmer, R., Müller, S., Pawson, T. J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.013 · Cited by 1,719 · see citing works

Structure of Bcl-x _L -Bak Peptide Complex: Recognition Between Regulators of Apoptosis

Sattler, M., Liang, H., Nettesheim, D., Meadows, R. P., Harlan, J. E., Eberstadt, M., Yoon, H. S., Shuker, S. B., Chang, B. S., Minn, A. J., et al. (1997) · Science · doi:10.1126/science.275.5302.983 · Cited by 1,476 · see citing works

Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix

Walensky, L. D., Kung, A. L., Escher, I., Malia, T. J., Barbuto, S., Wright, R. D., Wagner, G., Verdine, G. L., & Korsmeyer, S. J. (2004) · Science · doi:10.1126/science.1099191 · Cited by 1,349 · see citing works

Epigenetic protein families: a new frontier for drug discovery

Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327 · see citing works

Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells

Wang, J., Liu, D., Zhang, Z., Shan, S., Han, X., Srinivasula, S. M., Croce, C. M., Alnemri, E. S., & Huang, Z. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.13.7124 · Cited by 1,201 · see citing works

A decade of fragment-based drug design: strategic advances and lessons learned

Hajduk, P. J., & Greer, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2220 · Cited by 1,068 · see citing works

Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality

Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065 · see citing works

A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis

Srinivasula, S. M., Hegde, R. P., Saleh, A., Datta, P., Shiozaki, E. N., Chai, J., Lee, R., Robbins, P. D., Fernandes‐Alnemri, T., Shi, Y., et al. (2001) · Nature · doi:10.1038/35065125 · Cited by 1,013 · see citing works

Protein-Protein Interaction Detection: Methods and Analysis

Rao, V. S., Srinivas, K., Sujini, G. N., & Kumar, G. N. S. (2014) · International Journal of Proteomics · doi:10.1155/2014/147648 · Cited by 811 · see citing works

Hydrocarbon-Stapled Peptides: Principles, Practice, and Progress

Walensky, L. D., & Bird, G. H. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4011675 · Cited by 803 · see citing works

Electrostatic aspects of protein–protein interactions

Sheinerman, F. B., Norel, R., & Honig, B. H. (2000) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(00)00065-8 · Cited by 763 · see citing works

Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer

Padmanabhan, B., Tong, K. I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., Kang, M.-I., Kobayashi, A., Yokoyama, S., & Yamamoto, M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.013 · Cited by 735 · see citing works

On the Value of c : Can Low Affinity Systems Be Studied by Isothermal Titration Calorimetry?

Turnbull, W. B., & Daranas, A. H. (2003) · Journal of the American Chemical Society · doi:10.1021/ja036166s · Cited by 725 · see citing works

Structure-based prediction of protein–protein interactions on a genome-wide scale

Zhang, Q. C., Petrey, D., Deng, L., Qiang, L., Shi, Y., Thu, C. A., Bisikirska, B., Lefebvre, C., Accili, D., Hunter, T., et al. (2012) · Nature · doi:10.1038/nature11503 · Cited by 723 · see citing works

β-Peptidic Peptidomimetics

Seebàch, D., & Gardiner, J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700263g · Cited by 711 · see citing works

Insights into DNA recombination from the structure of a RAD51–BRCA2 complex

Pellegrini, L., Yu, D. S., Lo, T., Anand, S., Lee, M., Blundell, T. L., & Venkitaraman, A. R. (2002) · Nature · doi:10.1038/nature01230 · Cited by 704 · see citing works

Principles of Protein−Protein Interactions: What are the Preferred Ways For Proteins To Interact?

Keskin, O., Gursoy, A., Ma, B., & Nussinov, R. (2008) · Chemical Reviews · doi:10.1021/cr040409x · Cited by 697 · see citing works

Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery

Lo, M.-C., AULABAUGH, A. E., Jin, G., Cowling, R. A., Bard, J., Malamas, M. S., & Ellestad, G. A. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.04.031 · Cited by 688 · see citing works

Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling

Lo, S., Li, X., Henzl, M. T., Beamer, L. J., & Hannink, M. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601243 · Cited by 604 · see citing works

Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling

Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S. A., Triola, G., Wittinghofer, A., Bastiaens, P. I. H., et al. (2013) · Nature · doi:10.1038/nature12205 · Cited by 596 · see citing works

Protein–protein interactions: Structurally conserved residues distinguish between binding sites and exposed protein surfaces

Ma, B., Elkayam, T., Wolfson, H., & Nussinov, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1030237100 · Cited by 595 · see citing works

Dissecting protein–protein recognition sites

Chakrabarti, P., & Janin, J. (2002) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.10085 · Cited by 571 · see citing works

Crystal Structure of the Bcl-XL-Beclin 1 Peptide Complex

Oberstein, A., Jeffrey, P. D., & Shi, Y. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700492200 · Cited by 567 · see citing works

Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL

Degterev, A., Lugovskoy, A. A., Cardone, M. H., Mulley, B., Wagner, G., Mitchison, T. J., & Yuan, J. (2001) · Nature Cell Biology · doi:10.1038/35055085 · Cited by 550 · see citing works

High-throughput crystallography for lead discovery in drug design

Blundell, T. L., Jhoti, H., & Abell, C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd706 · Cited by 529 · see citing works

Druggability Indices for Protein Targets Derived from NMR-Based Screening Data

Hajduk, P. J., Huth, J. R., & Fesik, S. W. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049131r · Cited by 525 · see citing works

Hot Regions in Protein–Protein Interactions: The Organization and Contribution of Structurally Conserved Hot Spot Residues

Keskin, O., Ma, B., & Nussinov, R. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.10.077 · Cited by 519 · see citing works

Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication

Christ, F., Voet, A., Marchand, A., Nicolet, S., Desimmie, B. A., Marchand, D., Bardiot, D., Van der Veken, N. J., Van Remoortel, B., Strelkov, S. V., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.370 · Cited by 479 · see citing works

Site-directed ligand discovery

Erlanson, D. A., Braisted, A. C., Raphael, D. R., Randal, M., Stroud, R. M., Gordon, E. M., & Wells, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.17.9367 · Cited by 466 · see citing works

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment

Zhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501092z · Cited by 462 · see citing works

Integrins as therapeutic targets: lessons and opportunities

Cox, D. M., Brennan, M., & Moran, N. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3266 · Cited by 456 · see citing works

Different Electrostatic Potentials Define ETGE and DLG Motifs as Hinge and Latch in Oxidative Stress Response

Tong, K. I., Padmanabhan, B., Kobayashi, A., Shang, C., Hirotsu, Y., Yokoyama, S., & Yamamoto, M. P. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00753-07 · Cited by 447 · see citing works

Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells

Grasberger, B. L., Lu, T., Schubert, C., Parks, D. J., Carver, T. E., Koblish, H. K., Cummings, M. D., LaFrance, L. V., Milkiewicz, K. L., Calvo, R. R., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049137g · Cited by 433 · see citing works

The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer

Stewart, M. L., Fire, E., Keating, A. E., & Walensky, L. D. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.391 · Cited by 418 · see citing works

Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies

Petros, A. M., Nettesheim, D. G., Wang, Y., Olejniczak, E. T., Meadows, R. P., Mack, J. C., Swift, K. M., Matayoshi, E. D., Zhang, H., Thompson, C. B., et al. (2000) · Protein Science · doi:10.1110/ps.9.12.2528 · Cited by 413 · see citing works

Binding of small molecules to an adaptive protein–protein interface

Arkin, M. R., Randal, M., DeLano, W. L., Hyde, J., Luong, T. N., Oslob, J. D., Raphael, D. R., Taylor, L., Wang, J., McDowell, R. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.252756299 · Cited by 376 · see citing works

Discovery of Potent Antagonists of the Antiapoptotic Protein XIAP for the Treatment of Cancer

Oost, T. K., Sun, C. C., Armstrong, R. C., Al-Assaad, A.-S., Betz, S. F., Deckwerth, T. L., Ding, H., Elmore, S. W., Meadows, R. P., Olejniczak, E. T., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040037k · Cited by 367 · see citing works

Bcl-2 inhibitors: small molecules with a big impact on cancer therapy

Vogler, M., Dinsdale, D. D., Dyer, M. J. S., & Cohen, G. M. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.137 · Cited by 359 · see citing works

The Structure of a Bcl-xL/Bim Fragment Complex

Liu, X., Dai, S., Zhu, Y., Marrack, P., & Kappler, J. W. (2003) · Immunity · doi:10.1016/s1074-7613(03)00234-6 · Cited by 358 · see citing works

The 'rule of three' for fragment-based drug discovery: where are we now?

Jhoti, H., Williams, G., Rees, D. C., & Murray, C. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3926-c1 · Cited by 330 · see citing works

Discovery of Small-Molecule Inhibitors of Bcl-2 through Structure-Based Computer Screening

Enyedy, I. J., Ling, Y., Nacro, K., Tomita, Y. A., Wu, X., Cao, Y., Guo, R., Li, B., Zhu, X., Huang, Y. K., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010016f · Cited by 315 · see citing works

Predicting druggable binding sites at the protein–protein interface

Fuller, J. C., Burgoyne, N. J., & Jackson, R. M. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.10.009 · Cited by 311 · see citing works

Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains

Mirguet, O., Gosmini, R. L., Toum, J., Clément, C. A., Barnathan, M., Brusq, J.-M. G., Mordaunt, J. E., Grimes, R. M., Crowe, M. C., Pineau, O., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401088k · Cited by 310 · see citing works

Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL

Bruncko, M., Oost, T. K., Belli, B., Ding, H., Joseph, M. K., Kunzer, A. R., Martineau, D., McClellan, W. J., Mitten, M. J., Ng, S., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061152t · Cited by 306 · see citing works

Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX

Ku, B., Liang, C., Jung, J. U., & Oh, B. (2010) · Cell Research · doi:10.1038/cr.2010.149 · Cited by 304 · see citing works

Discovery of a Potent Inhibitor of the Antiapoptotic Protein Bcl-x L from NMR and Parallel Synthesis

Petros, A. M., Dinges, J., Augeri, D. J., Baumeister, S. A., Betebenner, D. A., Bures, M. G., Elmore, S. W., Hajduk, P. J., Joseph, M. K., Landis, S. K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0507532 · Cited by 295 · see citing works

Structure-Based Design of Potent Small-Molecule Inhibitors of Anti-Apoptotic Bcl-2 Proteins

Wang, G., Nikolovska‐Coleska, Z., Yang, C., Wang, R., Tang, G., Guo, J., Shangary, S. K., Qiu, S., Gao, W., Yang, D., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060460o · Cited by 293 · see citing works

BiGGER: A new (soft) docking algorithm for predicting protein interactions

Palma, P. N., Krippahl, L., Wampler, J. E., & Moura, J. J. G. (2000) · Proteins Structure Function and Bioinformatics · doi:10.1002/(sici)1097-0134(20000601)39:4 · Cited by 292 · see citing works

Contemporary strategies for the stabilization of peptides in the α-helical conformation

Henchey, L. K., Jochim, A. L., & Arora, P. S. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.08.019 · Cited by 289 · see citing works

Features of protein–protein interactions that translate into potent inhibitors: topology, surface area and affinity

Smith, M. C. P., & Gestwicki, J. E. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2012.10 · Cited by 285 · see citing works

Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family

Lee, E. F., Czabotar, P. E., Smith, B. J., Deshayes, K., Zobel, K., Colman, P. M., & Fairlie, W. D. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402178 · Cited by 280 · see citing works

A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment

Cai, Q., Sun, H., Peng, Y., Lü, J., Nikolovska‐Coleska, Z., McEachern, D., Liu, L., Qiu, S., Yang, C., Miller, R. S., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101505d · Cited by 274 · see citing works

Discovery of Potent Keap1–Nrf2 Protein–Protein Interaction Inhibitor Based on Molecular Binding Determinants Analysis

Jiang, Z., Lu, M., Xu, L., Yang, T., Xi, M., Xu, X., Guo, X., Zhang, X., You, Q., & Sun, H.-P. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5000529 · Cited by 263 · see citing works

Discovery of a Potent Small Molecule IL-2 Inhibitor through Fragment Assembly

Braisted, A. C., Oslob, J. D., DeLano, W. L., Hyde, J., McDowell, R. S., Waal, N. D., Yu, C. H., Arkin, M. R., & Raimundo, B. C. (2003) · Journal of the American Chemical Society · doi:10.1021/ja034247i · Cited by 256 · see citing works

Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism

Marcotte, D. J., Zeng, W., Hus, J., McKenzie, A., Hession, C., Jin, P., Bergeron, C., Lugovskoy, A. A., Enyedy, I. J., Cuervo, H., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.04.019 · Cited by 245 · see citing works

Multiple Independent Binding Sites for Small-Molecule Inhibitors on the Oncoprotein c-Myc

Hammoudeh, D. I., Follis, A. V., Prochownik, E. V., & Metallo, S. J. (2009) · Journal of the American Chemical Society · doi:10.1021/ja900616b · Cited by 232 · see citing works

Morphology of protein–protein interfaces

Larsen, T. A., Olson, A. J., & Goodsell, D. S. (1998) · Structure · doi:10.1016/s0969-2126(98)00044-6 · Cited by 228 · see citing works

Chemical and structural lessons from recent successes in protein–protein interaction inhibition (2P2I)

Morelli, X., Bourgeas, R., & Roche, P. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.05.024 · Cited by 223 · see citing works

Towards understanding cell penetration by stapled peptides

Chu, Q., Moellering, R. E., Hilinski, G. J., Kim, Y., Grossmann, T. N., Yeh, J. T. ‐., & Verdine, G. L. (2014) · MedChemComm · doi:10.1039/c4md00131a · Cited by 219 · see citing works

Beta-Strand Mimetics

Loughlin, W. A., Tyndall, J. D. A., Glenn, M. P., & Fairlie, D. P. (2004) · Chemical Reviews · doi:10.1021/cr040648k · Cited by 218 · see citing works

The Structure of Interleukin-2 Complexed with Its Alpha Receptor

Rickert, M., Wang, X., Boulanger, M. J., Goriatcheva, N., & García, K. C. (2005) · Science · doi:10.1126/science.1109745 · Cited by 212 · see citing works

Design, Synthesis, and Characterization of a Potent, Nonpeptide, Cell-Permeable, Bivalent Smac Mimetic That Concurrently Targets Both the BIR2 and BIR3 Domains in XIAP

Sun, H., Nikolovska‐Coleska, Z., Lü, J., Meagher, J. L., Yang, C., Qiu, S., Tomita, Y. A., Ueda, Y., Jiang, S., Krajewski, K., et al. (2007) · Journal of the American Chemical Society · doi:10.1021/ja074725f · Cited by 211 · see citing works

A first-draft human protein-interaction map

Lehner, B., & Fraser, A. G. (2004) · Genome biology · doi:10.1186/gb-2004-5-9-r63 · Cited by 211 · see citing works

Discovery of a small-molecule inhibitor and cellular probe of Keap1–Nrf2 protein–protein interaction

Hu, L., Magesh, S., Chen, L., Wang, L., Lewis, T. A., Chen, Y., Khodier, C., Inoyama, D., Beamer, L. J., Emge, T. J., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.013 · Cited by 206 · see citing works

A Conserved Arginine-containing Motif Crucial for the Assembly and Enzymatic Activity of the Mixed Lineage Leukemia Protein-1 Core Complex

Patel, A. B., Vought, V. E., Dharmarajan, V., & Cosgrove, M. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806317200 · Cited by 206 · see citing works

High-Affinity, Small-Molecule Peptidomimetic Inhibitors of MLL1/WDR5 Protein–Protein Interaction

Karataş, H., Townsend, E. C., Cao, F., Chen, Y., Bernard, D., Liu, L., Lei, M., Dou, Y., & Wang, S. (2012) · Journal of the American Chemical Society · doi:10.1021/ja306028q · Cited by 205 · see citing works

Dissecting Fragment-Based Lead Discovery at the von Hippel-Lindau Protein:Hypoxia Inducible Factor 1α Protein-Protein Interface

Molle, I. V., Thomann, A., Buckley, D. L., So, E. C., Lang, S., Crews, C. M., & Ciulli, A. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.08.015 · Cited by 198 · see citing works

Systematic Analysis of Helical Protein Interfaces Reveals Targets for Synthetic Inhibitors

Jochim, A. L., & Arora, P. S. (2010) · ACS Chemical Biology · doi:10.1021/cb1001747 · Cited by 191 · see citing works

Structural Rationale for the Coupled Binding and Unfolding of the c-Myc Oncoprotein by Small Molecules

Follis, A. V., Hammoudeh, D. I., Wang, H., Prochownik, E. V., & Metallo, S. J. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.09.011 · Cited by 183 · see citing works

Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery

Blundell, T. L., Sibanda, B. L., Montalvão, R. W., Brewerton, S. C., Chelliah, V., Worth, C. L., Harmer, N. J., Davies, O. R., & Burke, D. F. (2006) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2005.1800 · Cited by 178 · see citing works

Structure of WDR5 Bound to Mixed Lineage Leukemia Protein-1 Peptide

Patel, A. B., Dharmarajan, V., & Cosgrove, M. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.c800164200 · Cited by 173 · see citing works

Chimeric (α/β + α)-Peptide Ligands for the BH3-Recognition Cleft of Bcl-x L : Critical Role of the Molecular Scaffold in Protein Surface Recognition

Sadowsky, J., Schmitt, M. A., Lee, H., Umezawa, N., Wang, S., Tomita, Y. A., & Gellman, S. H. (2005) · Journal of the American Chemical Society · doi:10.1021/ja053678t · Cited by 173 · see citing works

Fragment-based hit identification: thinking in 3D

Morley, A., Pugliese, A., Birchall, K., Bower, J. F., Brennan, P. E., Brown, N., Chapman, T., Drysdale, M., Gilbert, I. H., Hoelder, S., et al. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.011 · Cited by 160 · see citing works

Structure-Based Design of Potent, Conformationally Constrained Smac Mimetics

Sun, H., Nikolovska‐Coleska, Z., Yang, C., Xu, L., Liu, M., Tomita, Y. A., Pan, H., Yoshioka, Y., Krajewski, K., Roller, P. P., et al. (2004) · Journal of the American Chemical Society · doi:10.1021/ja047438+ · Cited by 159 · see citing works

High‐Resolution Structural Characterization of a Helical α/β‐Peptide Foldamer Bound to the Anti‐Apoptotic Protein Bcl‐x L

Lee, E. F., Sadowsky, J., Smith, B. J., Czabotar, P. E., Peterson‐Kaufman, K. J., Colman, P. M., Gellman, S. H., & Fairlie, W. D. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200805761 · Cited by 159 · see citing works

Rapid Identification of Keap1–Nrf2 Small-Molecule Inhibitors through Structure-Based Virtual Screening and Hit-Based Substructure Search

Zhuang, C., Narayanapillai, S. C., Zhang, W., Sham, Y. Y., & Xing, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4017174 · Cited by 156 · see citing works

Atomic Interactions and Profile of Small Molecules Disrupting Protein–Protein Interfaces: the TIMBAL Database

Higueruelo, A. P., Schreyer, A. M., Bickerton, G. R., Pitt, W. R., Groom, C. R., & Blundell, T. L. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00889.x · Cited by 155 · see citing works

Flexibility and small pockets at protein–protein interfaces: New insights into druggability

Jubb, H. C., Blundell, T. L., & Ascher, D. B. (2015) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2015.01.009 · Cited by 154 · see citing works

Small-molecule inhibitors of the Myc oncoprotein

Fletcher, S., & Prochownik, E. V. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.005 · Cited by 153 · see citing works

Requirement of Both the Second and Third BIR Domains for the Relief of X-linked Inhibitor of Apoptosis Protein (XIAP)-mediated Caspase Inhibition by Smac

Huang, Y., Rich, R. L., Myszka, D. G., & Wu, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m310061200 · Cited by 152 · see citing works

Discovery and Optimization of Chromenotriazolopyrimidines as Potent Inhibitors of the Mouse Double Minute 2−Tumor Protein 53 Protein−Protein Interaction

Allen, J. G., Bourbeau, M. P., Wohlhieter, G. E., Bartberger, M. D., Michelsen, K., Hungate, R. W., Gadwood, R. C., Gaston, R. D., Evans, B., Mann, L. W., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900681h · Cited by 148 · see citing works

2P2Idb: a structural database dedicated to orthosteric modulation of protein–protein interactions

Basse, M. J., Betzi, S., Bourgeas, R., Bouzidi, S., Chetrit, B., Hamon, V., Morelli, X., & Roche, P. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1002 · Cited by 148 · see citing works

Peptide inhibitors of the Keap1–Nrf2 protein–protein interaction

Hancock, R., Bertrand, H. C., Tsujita, T., Naz, S., El-Bakry, A., Laoruchupong, J., Hayes, J. D., & Wells, G. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.486 · Cited by 147 · see citing works

Design, Synthesis, and Evaluation of an α-Helix Mimetic Library Targeting Protein−Protein Interactions

Shaginian, A., Whitby, L. R., Hong, S., Hwang, I., Farooqi, B., Searcey, M., Chen, J., Vogt, P. K., & Boger, D. L. (2009) · Journal of the American Chemical Society · doi:10.1021/ja810025g · Cited by 144 · see citing works

Hot-spot mimicry of a cytokine receptor by a small molecule

Thanos, C. D., DeLano, W. L., & Wells, J. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607058103 · Cited by 141 · see citing works

Probing Hot Spots at Protein−Ligand Binding Sites: A Fragment-Based Approach Using Biophysical Methods

Ciulli, A., Williams, G., Smith, A. G., Blundell, T. L., & Abell, C. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060490r · Cited by 135 · see citing works

Identification of a Small Molecule Inhibitor of the IL-2/IL-2Rα Receptor Interaction Which Binds to IL-2

Tilley, J., Chen, L., Fry, D. C., Emerson, S. D., Powers, G. D., Biondi, D. A., Varnell, T. A., Trilles, R. V., Guthrie, R. W., Mennona, F. A., et al. (1997) · Journal of the American Chemical Society · doi:10.1021/ja970702x · Cited by 129 · see citing works

Protein surface recognition and proteomimetics: mimics of protein surface structure and function

Fletcher, S., & Hamilton, A. D. (2005) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2005.10.006 · Cited by 129 · see citing works

Smac Mimetics and TNFα: A Dangerous Liaison?

Wu, H., Tschopp, J., & Lin, S. (2007) · Cell · doi:10.1016/j.cell.2007.10.042 · Cited by 128 · see citing works

Using a Fragment‐Based Approach To Target Protein–Protein Interactions

Scott, D. E., Ehebauer, M. T., Pukala, T. L., Marsh, M., Blundell, T. L., Venkitaraman, A. R., Abell, C., & Hyvönen, M. (2013) · ChemBioChem · doi:10.1002/cbic.201200521 · Cited by 123 · see citing works

A Novel Approach for Characterizing Protein Ligand Complexes: Molecular Basis for Specificity of Small-Molecule Bcl-2 Inhibitors

Lugovskoy, A. A., Degterev, A., Fahmy, A. F., Zhou, P., Gross, J. D., Yuan, J., & Wagner, G. (2002) · Journal of the American Chemical Society · doi:10.1021/ja011239y · Cited by 116 · see citing works

Biophysical and computational fragment-based approaches to targeting protein–protein interactions: applications in structure-guided drug discovery

Winter, A., Higueruelo, A. P., Marsh, M., Sigurdardottir, A., Pitt, W. R., & Blundell, T. L. (2012) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583512000108 · Cited by 115 · see citing works

Update 1 of: Beta-Strand Mimetics

Loughlin, W. A., Tyndall, J. D. A., Glenn, M. P., Hill, T. A., & Fairlie, D. P. (2010) · Chemical Reviews · doi:10.1021/cr900395y · Cited by 111 · see citing works

Discovery of Potent Mcl-1/Bcl-xL Dual Inhibitors by Using a Hybridization Strategy Based on Structural Analysis of Target Proteins

Tanaka, Y., Aikawa, K., Nishida, G., Homma, M., Sogabe, S., Igaki, S., Hayano, Y., Sameshima, T., Miyahisa, I., Kawamoto, T., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401170c · Cited by 111 · see citing works

ANCHOR: a web server and database for analysis of protein-protein interaction binding pockets for drug discovery

Meireles, L., Dömling, A. S. S., & Camacho, C. J. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq502 · Cited by 108 · see citing works

The structure of interfaces between subunits of dimeric and tetrameric proteins

Miller, S. (1989) · Protein Engineering Design and Selection · doi:10.1093/protein/3.2.77 · Cited by 106 · see citing works

Localization in human interleukin 2 of the binding site to the alpha chain (p55) of the interleukin 2 receptor.

Sauvé, K., Nachman-Clewner, M., Spence, C. L., Bailon, P., Campbell, E., Tsien, W. H., Kondas, J. A., Hakimi, J., & Ju, G. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.4636 · Cited by 100 · see citing works

p53 α-Helix mimetics antagonize p53/MDM2 interaction and activate p53

Chen, L., Yin, H. H., Farooqi, B., Sebti, S. M., Hamilton, A. D., & Chen, J. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0342 · Cited by 97 · see citing works

Compound Design by Fragment‐Linking

Ichihara, O., Barker, J. J., Law, R. J., & Whittaker, M. A. (2011) · Molecular Informatics · doi:10.1002/minf.201000174 · Cited by 95 · see citing works

Druggable Protein Interaction Sites Are More Predisposed to Surface Pocket Formation than the Rest of the Protein Surface

Johnson, D. K., & Karanicolas, J. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002951 · Cited by 92 · see citing works

Peptide inhibitors of the Keap1–Nrf2 protein–protein interaction with improved binding and cellular activity

Hancock, R., Schaap, M., Pfister, H., & Wells, G. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob40249e · Cited by 91 · see citing works

Atomic Structure of a Short α-Helix Stabilized by a Main Chain Hydrogen-Bond Surrogate

Liu, J., Wang, D., Zheng, Q., Lu, M., & Arora, P. S. (2008) · Journal of the American Chemical Society · doi:10.1021/ja077704u · Cited by 91 · see citing works

Modulation of Protein-Protein Interactions by Stabilizing/Mimicking Protein Secondary Structure Elements

de Vega, M. J. P., Martín‐Martinez, M., & González‐Muñiz, R. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607779318325 · Cited by 90 · see citing works

Breast Cancer Cells Can Evade Apoptosis-Mediated Selective Killing by a Novel Small Molecule Inhibitor of Bcl-2

Real, P. J., Cao, Y., Wang, R., Nikolovska‐Coleska, Z., Sanz‐Ortiz, J., Wang, S., & Fernández-Luna, J. L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0945 · Cited by 89 · see citing works

Conformational Changes in Bcl-2 Pro-survival Proteins Determine Their Capacity to Bind Ligands

Lee, E. F., Czabotar, P. E., Yang, H. J., Sleebs, B. E., Lessène, G., Colman, P. M., Smith, B. J., & Fairlie, W. D. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.040725 · Cited by 87 · see citing works

Drugging challenging targets using fragment-based approaches

Coyne, A. G., Scott, D. E., & Abell, C. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.02.010 · Cited by 86 · see citing works

Integrating Fragment Assembly and Biophysical Methods in the Chemical Advancement of Small-Molecule Antagonists of IL-2: An Approach for Inhibiting Protein−Protein Interactions

Raimundo, B. C., Oslob, J. D., Braisted, A. C., Hyde, J., McDowell, R. S., Randal, M., Waal, N. D., Wilkinson, J., Yu, C. H., & Arkin, M. R. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049967u · Cited by 86 · see citing works

Kinetic Analyses of Keap1–Nrf2 Interaction and Determination of the Minimal Nrf2 Peptide Sequence Required for Keap1 Binding Using Surface Plasmon Resonance

Chen, Y., Inoyama, D., Kong, A. T., Beamer, L. J., & Hu, L. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01240.x · Cited by 85 · see citing works

Synthesis of a 2,3‘;6‘,3‘ ‘-Terpyridine Scaffold as an α-Helix Mimetic

Davis, J. M., Truong, A., & Hamilton, A. D. (2005) · Organic Letters · doi:10.1021/ol0521228 · Cited by 84 · see citing works

Fragment Screening Using X-Ray Crystallography

Davies, T. G., & Tickle, I. J. (2011) · Topics in current chemistry · doi:10.1007/128_2011_179 · Cited by 82 · see citing works

Development of a fluorescence polarization assay to screen for inhibitors of the FtsZ/ZipA interaction

Kenny, C. H., Ding, W., Kelleher, K. S., Benard, S., Dushin, E. G., Sutherland, A. G., Mosyak, L., Kriz, R., & Ellestad, G. A. (2003) · Analytical Biochemistry · doi:10.1016/j.ab.2003.08.033 · Cited by 76 · see citing works

Heterocyclic α-helix mimetics for targeting protein–protein interactions

Biros, S. M., Moisan, L., Mann, E., Carella, A., Zhai, D., Reed, J. C., & REBEK, J. J. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.075 · Cited by 75 · see citing works

Design of Bcl-2 and Bcl-xL Inhibitors with Subnanomolar Binding Affinities Based upon a New Scaffold

Zhou, H., Chen, J., Meagher, J. L., Yang, C., Aguilar, A., Liu, L., Bai, L., Cong, X., Cai, Q., Fang, X., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300178u · Cited by 73 · see citing works

Quinazoline Sulfonamides as Dual Binders of the Proteins B-Cell Lymphoma 2 and B-Cell Lymphoma Extra Long with Potent Proapoptotic Cell-Based Activity

Sleebs, B. E., Czabotar, P. E., Fairbrother, W. J., Fairlie, W. D., Flygare, J. A., Huang, D. C. S., Kersten, W. J. A., Koehler, M. F. T., Lessène, G., Lowes, K. N., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101596e · Cited by 72 · see citing works

Inhibition of Human Papillomavirus DNA Replication by Small Molecule Antagonists of the E1-E2 Protein Interaction

White, P. W., Titolo, S., Brault, K., Thauvette, L., Pelletier, A., Welchner, E., Bourgon, L., Doyon, L., Ogilvie, W. W., Yoakim, C., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303608200 · Cited by 71 · see citing works

Small-Molecule Inhibitors of IL-2/IL-2R: Lessons Learned and Applied

Wilson, C. G. M., & Arkin, M. R. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_93 · Cited by 70 · see citing works

Computational Drug Design Targeting Protein-Protein Interactions

Bienstock, R. J. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799436449 · Cited by 70 · see citing works

From Crystal Packing to Molecular Recognition: Prediction and Discovery of a Binding Site on the Surface of Polo‐Like Kinase 1

Sledz, P., Stubbs, C. J., Lang, S., Yang, Y., McKenzie, G. J., Venkitaraman, A. R., Hyvönen, M., & Abell, C. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201008019 · Cited by 69 · see citing works

Fragment-Based Deconstruction of Bcl-x L Inhibitors

Barelier, S., Pons, J., Marcillat, O., Lancelin, J., & Krimm, I. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100009z · Cited by 68 · see citing works

Terephthalamide derivatives as mimetics of the helical region of Bak peptide target Bcl-xL protein

Yin, H. H., & Hamilton, A. D. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.09.096 · Cited by 67 · see citing works

Comprehensive, atomic-level characterization of structurally characterized protein-protein interactions: the PICCOLO database

Bickerton, G. R., Higueruelo, A. P., & Blundell, T. L. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-313 · Cited by 66 · see citing works

Deconstruction of a Nutlin: Dissecting the Binding Determinants of a Potent Protein–Protein Interaction Inhibitor

Fry, D. C., Wartchow, C. A., Graves, B. J., Janson, C. A., Lukacs, C., Kammlott, U., Belunis, C. J., Palme, S., Klein, C., & Vu, B. T. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400062c · Cited by 59 · see citing works

Novel protein–protein interaction inhibitor of Nrf2–Keap1 discovered by structure-based virtual screening

Sun, H.-P., Jiang, Z., Zhang, M.-Y., Lu, M., Yang, T., Pan, Y., Huang, H., Zhang, X., & You, Q. (2013) · MedChemComm · doi:10.1039/c3md00240c · Cited by 59 · see citing works

Emerging Role of Surface Plasmon Resonance in Fragment-Based Drug Discovery

Navratilova, I. H., & Hopkins, A. L. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.128 · Cited by 58 · see citing works

Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2

Cossu, F., Mastrangelo, E., Milani, M., Sorrentino, G., Lecis, D., Delia, D., Manzoni, L., Seneci, P., Scolastico, C., & Bolognesi, M. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.10.139 · Cited by 57 · see citing works

Structure-function relationships for the interleukin 2 receptor: location of ligand and antibody binding sites on the Tac receptor chain by mutational analysis.

Robb, R. J., Rusk, C. M., & Neeper, M. P. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.15.5654 · Cited by 56 · see citing works

Fragment-Based Design of Small Molecule X-Linked Inhibitor of Apoptosis Protein Inhibitors

Huang, J., Zhang, Z., Wu, B., Cellitti, J. F., Zhang, X., Dahl, R. S., Shiau, C., Welsh, K., Emdadi, A., Stebbins, J. L., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8006992 · Cited by 55 · see citing works

Rational design of protein–protein interaction inhibitors

Rognan, D. (2014) · MedChemComm · doi:10.1039/c4md00328d · Cited by 55 · see citing works

Structure-Based Design of Small-Molecule Protein–Protein Interaction Modulators: The Story so Far

Falchi, F., Caporuscio, F., & Recanatini, M. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.13.204 · Cited by 54 · see citing works

Thermodynamic Properties of Water Molecules at a Protein–Protein Interaction Surface

Huggins, D. J., Marsh, M., & Payne, M. C. (2011) · Journal of Chemical Theory and Computation · doi:10.1021/ct200465z · Cited by 53 · see citing works

Small Molecule Inhibitors of the LEDGF Site of Human Immunodeficiency Virus Integrase Identified by Fragment Screening and Structure Based Design

Peat, T. S., Rhodes, D. I., Vandegraaff, N., Le, G. T., Smith, J. A., Clark, L. J., Jones, E. D., Coates, J. A. V., Thienthong, N., Newman, J. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040147 · Cited by 52 · see citing works

Effects of Conformational Dynamics on Predicted Protein Druggability

Brown, S. P., & Hajduk, P. J. (2006) · ChemMedChem · doi:10.1002/cmdc.200500013 · Cited by 52 · see citing works

Discovery and Characterization of Cooperative Ligand Binding in the Adaptive Region of Interleukin-2

Hyde, J., Braisted, A. C., Randal, M., & Arkin, M. R. (2003) · Biochemistry · doi:10.1021/bi034138g · Cited by 49 · see citing works

Design and modular parallel synthesis of a MCR derived α-helix mimetic protein–protein interaction inhibitor scaffold

Antuch, W., Menon, S., Chen, Q., Lu, Y., Sakamuri, S., Beck, B., Schauer-Vukašinović, V., Agarwal, S., Hess, S., & Dömling, A. S. S. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.11.102 · Cited by 48 · see citing works

The Overlap of Small Molecule and Protein Binding Sites within Families of Protein Structures

Davis, F. P., & Šali, A. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000668 · Cited by 45 · see citing works

Small‐Molecule Inhibitors That Target Protein–Protein Interactions in the RAD51 Family of Recombinases

Scott, D. E., Coyne, A. G., Venkitaraman, A. R., Blundell, T. L., Abell, C., & Hyvönen, M. (2014) · ChemMedChem · doi:10.1002/cmdc.201402428 · Cited by 42 · see citing works

Macrocyclization in the Design of Grb2 SH2 Domain-Binding Ligands Exhibiting High Potency in Whole-Cell Systems

Wei, C.-Q., Gao, Y., Lee, K., Guo, R., Li, B., Zhang, M., Yang, D., & Burke, T. R. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0203635 · Cited by 41 · see citing works

The Use of Chlorobenzene as a Probe Molecule in Molecular Dynamics Simulations

Tan, Y. S., Spring, D. R., Abell, C., & Verma, C. S. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500215x · Cited by 40 · see citing works

Optimization of Benzodiazepinones as Selective Inhibitors of the X-Linked Inhibitor of Apoptosis Protein (XIAP) Second Baculovirus IAP Repeat (BIR2) Domain

Kester, R. F., Donnell, A. F., Lou, Y., Remiszewski, S., Lombardo, L. J., Chen, S., Le, N. T., Lo, J. C. Y., Moliterni, J., Han, X., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400732v · Cited by 39 · see citing works

Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists

Perez, H. L., Banfi, P., Bertrand, J. A., Cai, Z., Grebinski, J. W., Kim, K., Lippy, J., Modugno, M., Naglich, J. G., Schmidt, R. J., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.04.103 · Cited by 36 · see citing works

Magic bullets in nature's arsenal

Kritzer, J. A. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.407 · Cited by 34 · see citing works

Targeting the BH3 Domain Mediated Protein−Protein Interaction of Bcl-xL through Virtual Screening

Mukherjee, P. K., Desai, P. V., Zhou, Y., & Avery, M. A. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci1000373 · Cited by 33 · see citing works

Screening Multicomponent Reactions for X-Linked Inhibitor of Apoptosis-Baculoviral Inhibitor of Apoptosis Protein Repeats Domain Binder

Monfardini, I., Huang, J., Beck, B., Cellitti, J. F., Pellecchia, M., & Dömling, A. S. S. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101341m · Cited by 30 · see citing works

Benzazepinones and Benzoxazepinones as Antagonists of Inhibitor of Apoptosis Proteins (IAPs) Selective for the Second Baculovirus IAP Repeat (BIR2) Domain

Donnell, A. F., Michoud, C., Rupert, K. C., Han, X., Aguilar, D., Frank, K. B., Fretland, A. J., Gao, L., Goggin, B. S., Hogg, J. H., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400731m · Cited by 28 · see citing works

Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2–p53 and MDMX–p53 protein–protein interactions

Blackburn, T. J., Ahmed, S. U., Coxon, C. R., Liu, J., Lü, X., Golding, B. T., Griffin, R. J., Hutton, C., Newell, D. R., Ojo, O. S., et al. (2013) · MedChemComm · doi:10.1039/c3md00161j · Cited by 27 · see citing works

Inhibition of bromodomain-mediated protein–protein interactions as a novel therapeutic strategy

Furdas, S. D., Carlino, L., Sippl, W., & Jung, M. (2011) · MedChemComm · doi:10.1039/c1md00201e · Cited by 26 · see citing works

Physico-Chemical and Computational Approaches to Drug Discovery

Luque, F. J. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849735377 · Cited by 25 · see citing works

Dr. PIAS: an integrative system for assessing the druggability of protein-protein interactions

Sugaya, N., & Furuya, T. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-50 · Cited by 24 · see citing works

Fragment-based drug discovery and protein–protein interactions

Turnbull, A. P., Boyd, S., & Walse, B. (2014) · Research and Reports in Biochemistry · doi:10.2147/rrbc.s28428 · Cited by 21 · see citing works

Development of a Phosphatase-Stable Phosphotyrosyl Mimetic Suitably Protected for the Synthesis of High-Affinity Grb2 SH2 Domain-Binding Ligands

Wei, C.-Q., Li, B., Guo, R., Yang, D., & Burke, T. R. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00527-9 · Cited by 19 · see citing works

Design and Synthesis of a Prototype Scaffold for Five‐Residue α‐Helix Mimetics

Bayly, A. R., White, A. J. P., & Spivey, A. C. (2013) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201300478 · Cited by 15 · see citing works

Protein-Protein Interactions: Recent Progress in the Development of Selective PDZ Inhibitors

Ducki, S., & Bennett, E. (2009) · Current Chemical Biology · doi:10.2174/2212796810903020146 · Cited by 15 · see citing works

Picking up the pieces with FBDD or FADD: invest early for future success

Whittaker, M. A. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.05.011 · Cited by 15 · see citing works

Predicting where Small Molecules Bind at Protein-Protein Interfaces

Walter, P., Metzger, J., Thiel, C., & Helms, V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058583 · Cited by 13 · see citing works

Protein–Protein Interaction Inhibitors: Case Studies on Small Molecules and Natural Compounds

Ferrari, S., Pellati, F., & Costi, M. P. (2013) · Springer eBooks · doi:10.1007/978-3-642-37999-4_2 · Cited by 11 · see citing works

Disruption of Protein-Protein Interfaces

Mangani, S. (2013) · Springer eBooks · doi:10.1007/978-3-642-37999-4 · Cited by 11 · see citing works

Protein-Protein Interactions as Drug Targets

Wendt, M. D. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_1 · Cited by 9 · see citing works

Aging and DNA Methylation

Kim, J., Kim, J.-Y., & Issa, J. J. (2009) · Current Chemical Biology · doi:10.2174/2212796810903010001 · Cited by 9 · see citing works

Rational Design Strategies for Developing Synthetic Inhibitors of Helical Protein Interfaces

Mahon, A. B., Miller, S. E., Joy, S. T., & Arora, P. S. (2012) · Topics in medicinal chemistry · doi:10.1007/978-3-642-28965-1_6 · Cited by 5 · see citing works

Computational Strategies and Challenges for Targeting Protein–Protein Interactions with Small Molecules

Grimme, D., González-Ruiz, D., & Gohlke, H. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849735377-00319 · Cited by 4 · see citing works

NMR in fragment-based drug discovery

Lepre, C. A., Connolly, P. J., & Moore, J. M. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511730412.006 · Cited by 2 · see citing works

Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies.

Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138 · see citing works

Electrochemical strategies for C–H functionalization and C–N bond formation

Kärkäs, M. D. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00619e · Cited by 1,008 · see citing works

Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials

Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891 · see citing works

Machine Learning in Drug Discovery: A Review

Dara, S., Dhamercherla, S., Jadav, S. S., Babu, C. M., & Ahsan, M. J. (2021) · Artificial Intelligence Review · doi:10.1007/s10462-021-10058-4 · Cited by 843 · see citing works

Roles of METTL3 in cancer: mechanisms and therapeutic targeting

Zeng, C., Huang, W., Li, Y., & Weng, H. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00951-w · Cited by 635 · see citing works

Spirocyclic Scaffolds in Medicinal Chemistry

Hiesinger, K., Dar’in, D. V., Proschak, E., & Krasavin, M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01473 · Cited by 626 · see citing works

Molecular Docking: Challenges, Advances and its Use in Drug Discovery Perspective

Saikia, S., & Bordoloi, M. (2018) · Current Drug Targets · doi:10.2174/1389450119666181022153016 · Cited by 576 · see citing works

Molecular photoswitches in aqueous environments

Volarić, J., Szymański, W., Simeth, N. A., & Feringa, B. L. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00547a · Cited by 439 · see citing works

Clinical targeting of HIV capsid protein with a long-acting small molecule

Link, J. O., Rhee, M. S., Tse, W. C., Zheng, J., Somoza, J. R., Rowe, W., Begley, R., Chiu, A., Mulato, A. S., Hansen, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2443-1 · Cited by 434 · see citing works

Ruthenium-Catalyzed Azide Alkyne Cycloaddition Reaction: Scope, Mechanism, and Applications

Johansson, J. R., Beke‐Somfai, T., Stålsmeden, A. S., & Kann, N. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00466 · Cited by 413 · see citing works

Overcoming Endosomal Entrapment in Drug Delivery

Pei, D., & Buyanova, M. Y. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00778 · Cited by 405 · see citing works

Asymmetric organocatalysis: an enabling technology for medicinal chemistry

Han, B., He, X., Liu, Y., He, G., Peng, C. Y., & Li, J. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00196a · Cited by 405 · see citing works

Deep learning in bioinformatics: Introduction, application, and perspective in the big data era

Li, Y., Huang, C., Ding, L., Li, Z., Pan, Y., & Gao, X. (2019) · Methods · doi:10.1016/j.ymeth.2019.04.008 · Cited by 401 · see citing works

Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis

Bieber, T. (2020) · Allergy · doi:10.1111/all.13954 · Cited by 382 · see citing works

MYC protein interactors in gene transcription and cancer

Lourenco, C., Resetca, D., Redel, C., Lin, P., MacDonald, A. S., Ciaccio, R., Kenney, T. M. G., Wei, Y., Andrews, D. W., Sunnerhagen, M., et al. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00367-9 · Cited by 341 · see citing works

Complete protein–protein association kinetics in atomic detail revealed by molecular dynamics simulations and Markov modelling

Plattner, N., Doerr, S., Fabritiis, G. D., & Noé, F. (2017) · Nature Chemistry · doi:10.1038/nchem.2785 · Cited by 338 · see citing works

The emerging role of mass spectrometry-based proteomics in drug discovery

Meissner, F., Geddes‐McAlister, J., Mann, M., & Bantscheff, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00409-3 · Cited by 355 · see citing works

The post-translational modification, SUMOylation, and cancer (Review)

Han, Z., Feng, Y.-H., Gu, B.-H., Li, Y., & Chen, H. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4280 · Cited by 337 · see citing works

WD40 repeat domain proteins: a novel target class?

Schapira, M., Tyers, M., Torrent, M., & Arrowsmith, C. H. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.179 · Cited by 335 · see citing works

Therapeutic strategies targeting FOXO transcription factors

Calissi, G., Lam, E. W. ‐., & Link, W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0088-2 · Cited by 336 · see citing works

Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development

Sarkar, C., Das, B., Rawat, V. S., Wahlang, J. B., Nongpiur, A., Tiewsoh, I., Lyngdoh, N. M., Das, D., Bidarolli, M., & Sony, H. T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032026 · Cited by 347 · see citing works

RNA Display Methods for the Discovery of Bioactive Macrocycles

Huang, Y., Wiedmann, M. M., & Suga, H. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00430 · Cited by 309 · see citing works

How Big Is Too Big for Cell Permeability?

Matsson, P., & Kihlberg, J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00237 · Cited by 303 · see citing works

Artificial intelligence in drug design

Zhong, F., Xing, J., Li, X., Liu, X., Fu, Z., Xiong, Z., Lu, D., Wu, X., Zhao, J., Tan, X., et al. (2018) · Science China Life Sciences · doi:10.1007/s11427-018-9342-2 · Cited by 288 · see citing works

Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways

Chamilos, G., Lionakis, M. S., & Kontoyiannis, D. P. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix687 · Cited by 267 · see citing works

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations

Birkinshaw, R. W., Gong, J., Luo, C. S., Lio, D. S. S., White, C. A., Anderson, M. A., Blombery, P. A., Lessène, G., Majewski, I. J., Thijssen, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10363-1 · Cited by 260 · see citing works

Small-molecule discovery through DNA-encoded libraries

Peterson, A. A., & Liu, D. R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00713-6 · Cited by 260 · see citing works

NLRP3 inflammasome priming: A riddle wrapped in a mystery inside an enigma

McKee, C. M., & Coll, R. C. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mr0720-513r · Cited by 236 · see citing works

Bypassing Endocytosis: Direct Cytosolic Delivery of Proteins

Du, S., Liew, S. S., Li, L., & Yao, S. Q. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b06584 · Cited by 222 · see citing works

New insights into protein–protein interaction modulators in drug discovery and therapeutic advance

Nada, H., Choi, Y., Kim, S.-D., Jeong, K. S., Meanwell, N. A., & Lee, K. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02036-3 · Cited by 233 · see citing works

Improving oral bioavailability of cyclic peptides by N-methylation

Räder, A. F. B., Reichart, F., Weinmüller, M., & Kessler, H. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.08.031 · Cited by 221 · see citing works

Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction

Simonetta, K. R., Taygerly, J., Boyle, K., Basham, S. E., Padovani, C., Lou, Y., Cummins, T. J., Yung, S. L., von Soly, S. K., Kayser, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09358-9 · Cited by 217 · see citing works

Efficient targeted degradation via reversible and irreversible covalent PROTACs

Gabizon, R., Shraga, A., Gehrtz, P., Livnah, E., Gurwicz, N., Avram, L., Unger, T., Albeck, S., Shulman, Z., & London, N. (2020) · doi:10.26434/chemrxiv.11494398.v1 · Cited by 213 · see citing works

Unifying principles of bifunctional, proximity-inducing small molecules

Gerry, C. J., & Schreiber, S. L. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0469-1 · Cited by 199 · see citing works

Genome mining methods to discover bioactive natural products

Bauman, K. D., Butler, K. S., Moore, B. S., & Chekan, J. R. (2021) · Natural Product Reports · doi:10.1039/d1np00032b · Cited by 198 · see citing works

Cyclic Peptides as Drugs for Intracellular Targets: The Next Frontier in Peptide Therapeutic Development

Buckton, L. K., Rahimi, M. N., & McAlpine, S. R. (2020) · Chemistry - A European Journal · doi:10.1002/chem.201905385 · Cited by 194 · see citing works

Chasing molecular glue degraders: screening approaches

Domostegui, A., Nieto-Barrado, L., Perez-Lopez, C., & Mayor-Ruiz, C. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00197g · Cited by 200 · see citing works

Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor

Tanada, M., Tamiya, M., Matsuo, A., Chiyoda, A., Takano, K., Ito, T., Irie, M., Kotake, T., Takeyama, R., Kawada, H., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c03886 · Cited by 181 · see citing works

Macrocycles as protein–protein interaction inhibitors

Dougherty, P. G., Qian, Z., & Pei, D. (2017) · Biochemical Journal · doi:10.1042/bcj20160619 · Cited by 179 · see citing works

Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase: Structure–Activity Relationships Leading to the Chemical Probe (2 S ,4 R )-1-(( S )-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy- N -(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298)

Soares, P., Gadd, M. S., Frost, J., Galdeano, C., Ellis, L. C. J., Epemolu, O., Rocha, S., Read, K. D., & Ciulli, A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00675 · Cited by 180 · see citing works

Low-Temperature Plasma for Biology, Hygiene, and Medicine: Perspective and Roadmap

Laroussi, M., Bekeschus, S., Keidar, M., Bogaerts, A., Fridman, A., Lu, X., Ostrikov, K., Hori, M., Stapelmann, K., Miller, V., et al. (2021) · IEEE Transactions on Radiation and Plasma Medical Sciences · doi:10.1109/trpms.2021.3135118 · Cited by 174 · see citing works

PeSTo: parameter-free geometric deep learning for accurate prediction of protein binding interfaces

Krapp, L. F., Abriata, L. A., Rodríguez, F. C., & Peraro, M. D. (2023) · Nature Communications · doi:10.1038/s41467-023-37701-8 · Cited by 159 · see citing works

Haven't got a glue: Protein surface variation for the design of molecular glue degraders

Kozicka, Z., & Thomä, N. H. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.009 · Cited by 170 · see citing works

The many faces of compartmentalized PKA signalosomes

Torres‐Quesada, O., Mayrhofer, J. E., & Stefan, E. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.05.012 · Cited by 160 · see citing works

Orally Active Peptides: Is There a Magic Bullet?

Räder, A. F. B., Weinmüller, M., Reichart, F., Schumacher‐Klinger, A., Merzbach, S., Gilon, C., Hoffman, A., & Kessler, H. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201807298 · Cited by 163 · see citing works

From Discovery to Bedside: Targeting the Ubiquitin System

Wertz, I. E., & Wang, X. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.10.022 · Cited by 157 · see citing works

Passive immunotherapies targeting Aβ and tau in Alzheimer's disease

Plotkin, S. S., & Cashman, N. R. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105010 · Cited by 156 · see citing works

The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics

Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 156 · see citing works

Protein–Small Molecule Interactions in Native Mass Spectrometry

Bennett, J. L., Nguyen, G. T. H., & Donald, W. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00293 · Cited by 159 · see citing works

DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs

Li, F., Hu, Q., Zhang, X., Sun, R., Liu, Z., Wu, S., Tian, S., Ma, X., Dai, Z., Yang, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34807-3 · Cited by 159 · see citing works

Rational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions

Wang, X., Ni, D., Liu, Y., & Lu, S. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.682675 · Cited by 153 · see citing works

Proteomimetics as protein-inspired scaffolds with defined tertiary folding patterns

Horne, W. S., & Grossmann, T. N. (2020) · Nature Chemistry · doi:10.1038/s41557-020-0420-9 · Cited by 145 · see citing works

Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein–Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2

Bojadzic, D., Alcazar, O., Chen, J., Chuang, S.-T., Capcha, J. M. C., Shehadeh, L. A., & Buchwald, P. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00070 · Cited by 143 · see citing works

Conversion and degradation pathways of sulfoximines

Wiezorek, S., Lamers, P., & Bolm, C. (2019) · Chemical Society Reviews · doi:10.1039/c9cs00483a · Cited by 141 · see citing works

De novo development of small cyclic peptides that are orally bioavailable

Merz, M. L., Habeshian, S., Li, B., David, J.-A. G. L., Nielsen, A. L., Ji, X., Khwildy, K. I., Benitez, M. M. D., Phothirath, P., & Heinis, C. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01496-y · Cited by 141 · see citing works

Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6

McCoull, W., Cheung, T., Anderson, E., Barton, P., Burgess, J., Byth, K., Cao, Q., Castaldi, M. P., Chen, H., Chiarparin, E., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00698 · Cited by 139 · see citing works

Pharmacological Targeting of IRE1 in Cancer

Raymundo, D. P., Doultsinos, D., Guillory, X., Carlesso, A., Eriksson, L. A., & Chevet, É. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.07.006 · Cited by 136 · see citing works

Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds

Cruz-Migoni, A., Canning, P., Quevedo, C. E., Bataille, C. J. R., Béry, N., Miller, A., Russell, A. J., Phillips, S. E. V., Carr, S. B., & Rabbitts, T. H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811360116 · Cited by 135 · see citing works

Mendelian randomization for studying the effects of perturbing drug targets

Gill, D., Georgakis, M. K., Walker, V. M., Schmidt, A. F., Gkatzionis, A., Freitag, D. F., Finan, C., Hingorani, A. D., Howson, J. M. M., Burgess, S., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16544.2 · Cited by 280 · see citing works

Defining molecular glues with a dual-nanobody cannabidiol sensor

Cao, S., Kang, S., Mao, H., Yao, J., Gu, L., & Zheng, N. (2022) · Nature Communications · doi:10.1038/s41467-022-28507-1 · Cited by 125 · see citing works

Fragment-based covalent ligand discovery

Lu, W., Kostic, M., Zhang, T., Che, J., Patricelli, M. P., Jones, L. H., Chouchani, E. T., & Gray, N. S. (2021) · RSC Chemical Biology · doi:10.1039/d0cb00222d · Cited by 136 · see citing works

Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment

Quevedo, C. E., Cruz-Migoni, A., Béry, N., Miller, A., Tanaka, T. U., Petch, D., Bataille, C. J. R., Lee, L. Y. W., Fallon, P. S., Tulmin, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05707-2 · Cited by 132 · see citing works

Structure-Based Macrocycle Design in Small-Molecule Drug Discovery and Simple Metrics To Identify Opportunities for Macrocyclization of Small-Molecule Ligands

Cummings, M. D., & Sekharan, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01985 · Cited by 130 · see citing works

Radius measurement via super-resolution microscopy enables the development of a variable radii proximity labeling platform

Oakley, J. V., Buksh, B. F., Fernández, D. F., Oblinsky, D. G., Seath, C. P., Geri, J. B., Scholes, G. D., & MacMillan, D. W. C. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2203027119 · Cited by 129 · see citing works

Peptide Macrocyclization Inspired by Non-Ribosomal Imine Natural Products

Malins, L. R., deGruyter, J. N., Robbins, K. J., Scola, P. M., Eastgate, M. D., Ghadiri, M. R., & Baran, P. S. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b01624 · Cited by 127 · see citing works

Inhibition of the Ras/Raf interaction and repression of renal cancer xenografts in vivo by an enantiomeric iridium( iii ) metal-based compound

Liu, L., Wang, W., Huang, S., Hong, Y., Li, G., Lin, S., Tian, J., Cai, Z., Wang, H.-M. D., Ma, D., et al. (2017) · Chemical Science · doi:10.1039/c7sc00311k · Cited by 126 · see citing works

Inhibition of RNA-binding proteins with small molecules

Wu, P. (2020) · Nature Reviews Chemistry · doi:10.1038/s41570-020-0201-4 · Cited by 129 · see citing works

Are We Opening the Door to a New Era of Medicinal Chemistry or Being Collapsed to a Chemical Singularity?

Ivanenkov, Y. A., Zagribelnyy, B. A., & Aladinskiy, V. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00004 · Cited by 123 · see citing works

NMR as a “Gold Standard” Method in Drug Design and Discovery

Emwas, A.-H. M., Szczepski, K., Poulson, B. G., Chandra, K., McKay, R. T., Dhahri, M., Alahmari, F., Jaremko, Ł., Lachowicz, J. I., & Jaremko, M. (2020) · Molecules · doi:10.3390/molecules25204597 · Cited by 129 · see citing works

Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway

Wang, T., Wu, X., Guo, C., Zhang, K., Xu, J., Li, Z., & Jiang, S. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00990 · Cited by 117 · see citing works

Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery

Macalino, S. J. Y., Basith, S., Clavio, N. A. B., Chang, H., Kang, S., & Choi, S. (2018) · Molecules · doi:10.3390/molecules23081963 · Cited by 113 · see citing works

Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics

Collins, D. C., Sundar, R., Lim, J. S. J., & Yap, T. A. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.012 · Cited by 113 · see citing works

Hydroxyl-Group-Dominated Graphite Dots Reshape Laser Desorption/Ionization Mass Spectrometry for Small Biomolecular Analysis and Imaging

Shi, R., Dai, X., Li, W., Lü, F., Liu, Y., Qu, H., Li, H., Chen, Q., Tian, H., Wu, E., et al. (2017) · ACS Nano · doi:10.1021/acsnano.7b05328 · Cited by 112 · see citing works

Structural and Biophysical Insights into the Function of the Intrinsically Disordered Myc Oncoprotein

Beaulieu, M.-È., Castillo, F., & Soucek, L. (2020) · Cells · doi:10.3390/cells9041038 · Cited by 110 · see citing works

Disease modification in inflammatory skin disorders: opportunities and challenges

Bieber, T. R. M. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00735-0 · Cited by 115 · see citing works

Design principles for cyclin K molecular glue degraders

Kozicka, Z., Suchyta, D. J., Focht, V., Kempf, G., Petzold, G., Jentzsch, M., Zou, C., Di Genua, C., Donovan, K. A., Coomar, S., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-023-01409-z · Cited by 113 · see citing works

Advances in Peptidomimetics for Next-Generation Therapeutics: Strategies, Modifications, and Applications

Lombardi, L., Genio, V. D., Alberício, F., & Williams, D. R. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00989 · Cited by 126 · see citing works

Emerging roles of allosteric modulators in the regulation of protein‐protein interactions (PPIs): A new paradigm for PPI drug discovery

Ni, D., Lu, S., & Zhang, J. (2019) · Medicinal Research Reviews · doi:10.1002/med.21585 · Cited by 116 · see citing works

Site-Directed Fragment-Based Screening for the Discovery of Protein–Protein Interaction Stabilizers

Sijbesma, E., Hallenbeck, K. K., Leysen, S., de Vink, P. J., Skóra, L., Jahnke, W., Brunsveld, L., Arkin, M. R., & Ottmann, C. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b11658 · Cited by 110 · see citing works

Network analysis and in silico prediction of protein–protein interactions with applications in drug discovery

Murakami, Y., Tripathi, L. P., Prathipati, P., & Mizuguchi, K. (2017) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2017.02.005 · Cited by 110 · see citing works

Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1–Nuclear Factor Erythroid 2-Related Factor 2 (Keap1–Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases

Pallesen, J. S., Tran, K. T., & Bach, A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00358 · Cited by 111 · see citing works

Inhibitor of Apoptosis Protein (IAP) Antagonists in Anticancer Agent Discovery: Current Status and Perspectives

Cong, H., Xu, L., Wu, Y., Qu, Z., Bian, T., Zhang, W., Xing, C., & Zhuang, C. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01668 · Cited by 113 · see citing works

PDZ Domains as Drug Targets

Christensen, N. R., Čalyševa, J., Fernandes, E. F. A., Lüchow, S., Clemmensen, L. S., Haugaard‐Kedström, L. M., & Strømgaard, K. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201800143 · Cited by 108 · see citing works

Tracking chromatin state changes using nanoscale photo-proximity labelling

Seath, C. P., Burton, A. J., Sun, X., Lee, G., Kleiner, R. E., MacMillan, D. W. C., & Muir, T. W. (2023) · Nature · doi:10.1038/s41586-023-05914-y · Cited by 110 · see citing works

Dengue drug discovery: Progress, challenges and outlook

Lim, S. P. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.12.016 · Cited by 105 · see citing works

Hot-spot analysis for drug discovery targeting protein-protein interactions

Rosell, M., & Fernández-Recio, J. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1430763 · Cited by 105 · see citing works

Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery

Li, Q., & Kang, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155262 · Cited by 103 · see citing works

Methylene Blue Inhibits the SARS-CoV-2 Spike–ACE2 Protein-Protein Interaction–a Mechanism that can Contribute to its Antiviral Activity Against COVID-19

Bojadzic, D., Alcazar, O., & Buchwald, P. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.600372 · Cited by 102 · see citing works

Artificial Intelligence (AI) in Drugs and Pharmaceuticals

Sahu, A., Mishra, J., & Kushwaha, N. (2021) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666211207153943 · Cited by 110 · see citing works

Bifunctional chemical probes inducing protein–protein interactions

Maniaci, C., & Ciulli, A. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.07.003 · Cited by 100 · see citing works

Identifying hydrophobic protein patches to inform protein interaction interfaces

Rego, N. B., Xi, E., & Patel, A. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2018234118 · Cited by 97 · see citing works

Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 space

Poongavanam, V., Doak, B. C., & Kihlberg, J. O. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.05.010 · Cited by 98 · see citing works

The design and development of covalent protein-protein interaction inhibitors for cancer treatment

Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00850-0 · Cited by 98 · see citing works

Genetic Code Expansion: Recent Developments and Emerging Applications

Huang, Y., Zhang, P., Wang, H., Chen, Y., Liu, T., & Luo, X. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00216 · Cited by 107 · see citing works

Aromatic clusters in protein–protein and protein–drug complexes

Lanzarotti, E., Defelipe, L. A., Marti, M. A., & Turjanski, A. G. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00437-4 · Cited by 93 · see citing works

Reactive intermediates for interactome mapping

Seath, C. P., Trowbridge, A., Muir, T. W., & MacMillan, D. W. C. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01366h · Cited by 93 · see citing works

Conformational Sampling of Macrocyclic Drugs in Different Environments: Can We Find the Relevant Conformations?

Poongavanam, V., Danelius, E., Peintner, S., Alcaraz, L., Caron, G., Cummings, M. D., Wlodek, S. T., Erdélyi, M., Hawkins, P. C. D., Ermondi, G., et al. (2018) · ACS Omega · doi:10.1021/acsomega.8b01379 · Cited by 92 · see citing works

Predicting and Experimentally Validating Hot-Spot Residues at Protein–Protein Interfaces

Ibarra, A. Á., Bartlett, G. J., Hegedüs, Z., Dutt, S., Hóbor, F., Horner, K. A., Hetherington, K., Spence, K., Nelson, A. S., Edwards, T. A., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00560 · Cited by 88 · see citing works

dMM-PBSA: A New HADDOCK Scoring Function for Protein-Peptide Docking

Spiliotopoulos, D., Kastritis, P. L., Melquiond, A. S. J., Bonvin, A. M. J. J., Musco, G., Rocchia, W., & Spitaleri, A. (2016) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2016.00046 · Cited by 90 · see citing works

Toward heterogeneous information fusion: bipartite graph convolutional networks for in silico drug repurposing

Wang, Z., Zhou, M., & Arnold, C. W. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa437 · Cited by 91 · see citing works

Small-molecule inhibitors of protein–protein interactions: progressing towards the dream

Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705 · see citing works

Protein-Protein Interactions as Drug Targets

Wendt, M. D. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_1 · Cited by 9 · see citing works

Protein–protein interactions as targets for small molecule drug discovery

Fry, D. C. (2006) · Biopolymers · doi:10.1002/bip.20608 · Cited by 203 · see citing works

Targeting Protein–Protein Interactions for Therapeutic Intervention: A Challenge for the Future

Zinzalla, G., & Thurston, D. E. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.12 · Cited by 257 · see citing works

Small-Molecule Inhibitors of Protein–Protein Interactions as Therapeutics

Poluri, K. M., Gulati, K., Tripathi, D. K., & Nagar, N. (2023) · Springer eBooks · doi:10.1007/978-981-99-2423-3_7 · Cited by 1 · see citing works